证券日报网讯 12月14日晚间，祥生医疗发布公告称，公司已于2025年12月10日在中国证券登记结算有 限公司上海分公司办理完成2025年限制性股票激励计划的股票授予登记工作，股本总数由112124537股 增至112125613股，注册资本相应由112124537.00元增至112125613.00元，并据此修订《公司章程》注册 资本及股份总数条款，办理工商变更登记。 （编辑 王江浩） ...

（编辑 王江浩） 证券日报网讯 12月14日晚间，祥生医疗发布公告称，2025年前三季度公司拟向全体股东每10股派发现 金红利3元（含税），合计拟派发现金红利33，562，425.90元（含税），本次利润分配不进行资本公积 转增股本，不送红股，尚需提交公司2025年第三次临时股东会审议通过后方可实施。 ...

Core Viewpoint - Xiangsheng Medical (688358) announced a cash dividend distribution plan for the first three quarters, proposing a cash dividend of 3 yuan per 10 shares to all shareholders, which reflects the company's commitment to returning value to its investors [1] Financial Performance - As of September 30, 2025, the total share capital of the company is 112,124,537 shares, with a base for the dividend calculation of 111,874,753 shares after deducting 249,784 shares held in the company's repurchase account [1] - The total cash dividend to be distributed amounts to 33.5624 million yuan (including tax), representing 35.73% of the net profit attributable to shareholders of the listed company as reported in the Q3 2025 consolidated financial statements [1] Business Overview - Xiangsheng Medical specializes in the research, development, manufacturing, and sales of ultrasound medical imaging equipment, having developed a comprehensive set of core technologies in ultrasound imaging, including 2D, 3D, and 4D ultrasound, as well as AI cloud platform solutions [1] - In the first three quarters of this year, the company achieved an operating income of 343 million yuan, a year-on-year decrease of 5.27%, and a net profit attributable to shareholders of 93.9205 million yuan, a year-on-year decrease of 4.56% [1]

Corporate Changes - Wang Ying, the chairman of Pudong Jinqiao, has resigned due to work transfer [2] - Xu Yinghui has become the new actual controller of Gu Ao Technology after a voting rights entrustment agreement [4][5] Profit Distribution - Xiangsheng Medical plans to distribute a cash dividend of 3 yuan per 10 shares for the first three quarters of 2025 [3] Investment Projects - Jiaze New Energy intends to invest approximately 3.557 billion yuan in a green hydrogen and methanol co-production project in Jixi City, Heilongjiang Province [6] - Longfei Optical Fiber's subsidiary plans to participate in establishing an investment fund with a total subscription amount of 830 million yuan [11] Financing Activities - Jinpan Technology has received approval from the China Securities Regulatory Commission to issue convertible bonds to unspecified investors [7] Acquisitions - Zoli Pharmaceutical has signed an agreement to acquire a multi-trace element injection asset group from Future Medicine for a total price of 356 million yuan [8] Product Approvals - Nine安 Medical's U.S. subsidiary has received pre-market notifications from the FDA for its multi-detection kits for various viruses [9] National Projects - Saiyi Information has been approved to lead a national major science and technology project focused on intelligent manufacturing systems and robotics [10]

祥生医疗表示，结合目前公司募集资金投资项目的实际建设情况和投资进度，在募集资金投资用途及投 资规模不发生变更的情况下，对研发创新及营销运营基地建设项目、创新与发展储备资金两个项目达到 预定可使用状态日期进行调整，原计划项目达到预定可使用状态日期为2025年12月31日。调整后，项目 达到预定可使用状态日期为2026年12月31日。 北京商报讯(记者丁宁)12月14日晚间，祥生医疗(688358)发布公告称，公司于12月12日召开第三届董事 会第十七次会议，审议通过了公司《关于部分募投项目延期的议案》，同意公司对部分募投项目达到预 定可使用状态的时间进行延期。 ...

Group 1 - Pudong Jinqiao's chairman Wang Ying has resigned due to job transfer, ceasing to hold positions as director, chairman, and committee member [2] - Xiangsheng Medical plans to distribute a cash dividend of 3 yuan per 10 shares to all shareholders based on the total share capital [3] - Gu Ao Technology's actual controller has changed to Xu Yinghui, with stock resuming trading on December 15 [4] Group 2 - Jiaze New Energy plans to invest approximately 3.557 billion yuan in a green hydrogen and aviation fuel chemical co-production project in Jixi City [5] - Jinpan Technology has received approval from the China Securities Regulatory Commission to issue convertible bonds to unspecified investors [6] - Zoli Pharmaceutical intends to acquire a multi-trace element injection asset group for a total price of 356 million yuan [7] Group 3 - Jiuan Medical's U.S. subsidiary has received pre-market notifications from the FDA for four and three-in-one testing products [8] - Saiyi Information has been approved for a national major science and technology project focusing on intelligent manufacturing systems and robotics [9] - Changfei Fiber's subsidiary plans to participate in establishing an investment fund with a total subscription amount of 830 million yuan [10] Group 4 - Chengfeng Technology's shareholder, Hangzhou Hongwo, plans to reduce its stake by up to 3% of the company's shares [12] - Minxin Co., Ltd.'s deputy general manager plans to reduce holdings by up to 220,000 shares, representing 0.3925% of the total share capital [13] - Xinle Energy's director plans to reduce holdings by up to 400,000 shares, accounting for 0.07% of the total share capital [14]

北京商报讯（记者 丁宁）12月14日晚间，祥生医疗（688358）发布2025年前三季度利润分配方案显 示，公司拟向全体股东每10股派发现金红利3元（含税）。 公告显示，此次分红合计拟派发现金红利3356.24万元（含税），本次公司现金分红金额占公司2025年 三季度报告合并报表归属净利润的比例为35.73%。 ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 祥生医疗（688358）发布前三季度利润分配方案。 12月14日，祥生医疗（688358）发布公告称，经公司第三届董事会第十七次会议审议通过，公司拟向全 体股东每10股派发现金红利3元（含税）。 截至2025年9月30日，公司总股本112，124，537股，扣除公司回购专用证券账户中股份数249，784股后 的股本111，874，753股为基数，以此计算合计拟派发现金红利3356.24万元（含税）。本次公司现金分 红金额占公司2025年三季度报告合并报表归属上市公司股东净利润的比例为35.73%。 公开资料显示，祥生医疗主营业务为超声医学影像设备研发、制造和销售。公司现已掌握了从二维超 声、三维超声到四维超声；从彩超探头核心部件、图像处理算法、图像分析软件到彩超整机设计开发； 从临床应用专科化、设备便携化到人工智能云平台解决方案在内的全套超声医学影像的核心技术。今年 前三季度，公司实现营业收入3.43亿元，同比减少5.27%；实现归母净利润9392.05万元，同比减少 4.56%。 | | | | 单位:元 | 币种:人民币 | | - ...

Core Viewpoint - Xiangsheng Medical (688358) announced a profit distribution plan for the first three quarters, proposing a cash dividend of 3 yuan per 10 shares to all shareholders, which reflects the company's commitment to returning value to its investors [2]. Financial Performance - As of September 30, 2025, the total share capital of the company is 112,124,537 shares, with a base for dividend calculation of 111,874,753 shares after deducting 249,784 shares in the repurchase account. The total proposed cash dividend amounts to 33.5624 million yuan (including tax), representing 35.73% of the net profit attributable to shareholders for the third quarter [5]. - For the first three quarters of the year, the company reported operating revenue of 343.166 million yuan, a decrease of 5.27% year-on-year. The net profit attributable to shareholders was 93.9205 million yuan, down 4.56% year-on-year [5][7]. - The total profit for the reporting period was 25.751 million yuan, showing a significant increase of 63.21% compared to the same period last year. However, the net profit attributable to shareholders decreased by 4.56% year-on-year [7]. Business Overview - Xiangsheng Medical specializes in the research, development, manufacturing, and sales of ultrasound medical imaging equipment. The company has developed a comprehensive set of core technologies in ultrasound imaging, including 2D, 3D, and 4D ultrasound, as well as AI cloud platform solutions [5].

证券代码：688358 证券简称：祥生医疗 公告编号：2025-045 无锡祥生医疗科技股份有限公司 2025 年股权激励计划限制性股票授予结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 限制性股票登记日 | 2025年12月10日 | | --- | --- | | 限制性股票登记数量 | 150,000股 | 一、股权激励计划前期基本情况 无锡祥生医疗科技股份股份有限公司（以下简称"公司"）2025 年限制性股 票激励计划（以下简称"本次激励计划"）方式为第一类限制性股票，股份来源为 公司自二级市场回购的本公司 A 股普通股股票及/或向激励对象定向发行的本公 司 A 股普通股股票，拟授予的权益数量为 160,000 股，占本激励计划公告日公司 总股本比例为 0.14%。本次授予为一次性授予，无预留权益。具体内容详见公司 2025 年 9 月 30 日披露于上海证券交易所官网（www.sse.com.cn）的《无锡祥生 医疗科技股份有限公司 2025 年限制性股票激励计划（草案）摘要》（公告编号 ...